Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring
platelet transfusion to maintain platelet counts. This investigational drug has been
demonstrated to increase platelet counts. This study will test the safety and efficacy of the
investigational drug in the prevention of thrombocytopenia in patients with recurrent or
refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or
Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin)
chemotherapy.